--- title: The Woolcock to advance inhaled peptide research with Quattrii DPI description: CHI collaborates with the Woolcock Institute to explore the Quattrii inhaler for delivering innovative antimicrobial therapies targeting lung infections. image: https://chi.uk/hubfs/Quattrii-carrier-free.jpg --- [Skip to content](https://chi.uk/chi-blog/the-woolcock-to-advance-inhaled-peptide-research-with-quattrii-dpi#main-content) Close - [ABOUT](https://chi.uk/about-us) - [Why work with us](https://chi.uk/about-us#Work-with-us) - [Our values](https://chi.uk/about-us#Values) - [The team](https://chi.uk/about-us#Meet-the-team) - [Where to find us](https://chi.uk/about-us#Contact) - [PRODUCTS](https://chi.uk/products) - [Quattrii](https://chi.uk/products#Quattrii) - [Aeolus](https://chi.uk/products#Aeolus) - [Occorix](https://chi.uk/products#Occorix) - [THE SCIENCE](https://chi.uk/the-science) - [VACANCIES](https://chi.uk/vacancies) - [BLOG](https://chi.uk/chi-blog) SEARCH Contact us [![logo](https://chi.uk/hubfs/CHI.svg "logo")](https://chi.uk/home) - [ABOUT](https://chi.uk/about-us) - [Why work with us](https://chi.uk/about-us#Work-with-us) - [Our values](https://chi.uk/about-us#Values) - [The team](https://chi.uk/about-us#Meet-the-team) - [Where to find us](https://chi.uk/about-us#Contact) - [PRODUCTS](https://chi.uk/products) - [Quattrii](https://chi.uk/products#Quattrii) - [Aeolus](https://chi.uk/products#Aeolus) - [Occorix](https://chi.uk/products#Occorix) - [THE SCIENCE](https://chi.uk/the-science) - [VACANCIES](https://chi.uk/vacancies) - [BLOG](https://chi.uk/chi-blog) Contact us Quick results for "{search\_term}" ![Quattrii-carrier-free](https://chi.uk/hs-fs/hubfs/Quattrii-carrier-free.jpg?width=300&name=Quattrii-carrier-free.jpg) [Jamie Greenwood](https://chi.uk/chi-blog/author/jamie-greenwood)Nov 13, 2026, 10:22:05 AM2 min read # The Woolcock to advance inhaled peptide research with Quattrii DPI [Previous](https://chi.uk/chi-blog/ucl-to-use-quattrii-to-advance-inhaled-antibody-and-rna-medicines) Australian research programme will evaluate CHI’s blister-based dry powder inhaler platform for delivery of novel antimicrobial formulations, with potential to treat persistent lung infections. CHI has announced a research collaboration with the Woolcock Institute of Medical Research in Sydney, Australia to evaluate its Quattrii™ dry powder inhaler for pulmonary delivery of spray-dried nisin, an antimicrobial peptide. The laboratory programme to test aerosol delivery will investigate how nisin formulations perform in the Quattrii DPI engine and whether a combination therapy of nisin and the antibiotic colistin warrants further evaluation. The collaboration addresses a practical barrier in developing new inhaled medicines: translating a promising powder into a reliably delivered aerosol at a useful dose. For antimicrobials, like all formulations, understanding how powder loading, dispersion and device retention affect delivery and potential for further biological evaluation and development is an important step towards assessing their potential for further development. The Woolcock brings expertise in respiratory formulation science, device characterisation, and drug delivery. Its researchers will complete aerosol testing with Quattrii across powder loads of 18 to 45 mg to help establish how formulation and device performance interact at different fill masses. The programme will also include preliminary testing against biofilms known to be difficult to treat. The results will guide whether development of a nisin–colistin co-formulation should be progressed. Professor Daniela Traini, the Woolcock's Respiratory Technology Research Leader, said: “Developing an inhaled antimicrobial is not just about producing a powder. We need to understand how much drug can actually reach the lungs and whether it retains its biological activity. “Working with CHI gives us the opportunity to evaluate Quattrii for delivering high doses of spray-dried nisin and to explore whether combining nisin with colistin could improve activity against difficult-to-treat bacterial biofilms.” Quattrii’s high powder capacity and overall flexibility make it suitable for a wide range of fill masses. Its individual heat-sealed aluminium foil blisters protect the formulation from moisture up to the point of use, while its unique, patented powder deagglomeration engine enables industry leading aerosol delivery. Devices are available now in moulded medical-grade plastic for laboratory evaluation and clinical trials. Jamie Greenwood, Principal Scientist at Cambridge Healthcare Innovations, said: “Tomorrow’s inhaled medicines need more than what yesterday’s inhalers can offer. They need devices that provide an effective way to protect and present the dose while still achieving class leading aerosol delivery performance. “Devices which have the ability to deliver across a range of powder loads, including high doses are valuable for next generation therapies, including biologic drugs. This collaboration will examine that relationship directly with our Quattrii carrier free dry powder inhaler. “We are delighted to support the Woolcock’s research into antimicrobial peptides. This is aligned with our aim to give formulation developers the right delivery device technology to support their development journey.” The programme is a non-clinical research evaluation and does not include human studies. Its findings will inform subsequent formulation and device development decisions. About the Woolcock Institute of Medical Research The Woolcock Institute of Medical Research is an Australian research institute focused on respiratory and sleep health. Its Respiratory Technology group brings together expertise in drug formulation, device development, characterisation and delivery. ![avatar](https://chi.uk/hs-fs/hubfs/Jamie.jpg?width=290&name=Jamie.jpg) #### [Jamie Greenwood](https://chi.uk/chi-blog/author/jamie-greenwood) Jamie is a versatile scientist bringing over 22 years of technical leadership in medical product development. His approach is data-driven, combining thorough planning with careful execution, insightful data analysis and compliant reporting. ## RELATED ARTICLES Button Title All rights reserved, Cambridge Healthcare Innovations Ltd 2024 - [Privacy policy](https://chi.uk/policies) - Registered in England & Wales (GB11540827) - [329 Cambridge Science Park, Cambridge CB4 0WG, UK](https://chi.uk/about-us#Contact) ```json { "@context" : "https://schema.org", "@type" : "Organization", "knowsLanguage" : "en", "logo" : { "@type" : "ImageObject", "url" : "https://144863708.fs1.hubspotusercontent-eu1.net/hubfs/144863708/CHI.svg" }, "name" : "", "url" : "https://chi.uk/chi-blog/the-woolcock-to-advance-inhaled-peptide-research-with-quattrii-dpi" } ``` ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "abstract" : "CHI collaborates with the Woolcock Institute to explore the Quattrii inhaler for delivering innovative antimicrobial therapies targeting lung infections.", "author" : { "@type" : "Person", "name" : "Jamie Greenwood" }, "dateModified" : "November 13, 2026 10 AM", "datePublished" : "November 13, 2026 10 AM", "headline" : "The Woolcock to advance inhaled peptide research with Quattrii DPI", "image" : "https://144863708.fs1.hubspotusercontent-eu1.net/hubfs/144863708/Quattrii-carrier-free.jpg", "inLanguage" : "en", "keywords" : "[Announcement, quattrii, Collaboration]", "mainEntityOfPage" : { "@type" : "WebPage" }, "name" : "The Woolcock to advance inhaled peptide research with Quattrii DPI", "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://144863708.fs1.hubspotusercontent-eu1.net/hubfs/144863708/CHI.svg" }, "name" : "" }, "text" : "Australian research programme will evaluate CHI’s blister-based dry powder inhaler platform for delivery of novel antimicrobial formulations, with potential to treat persistent lung infections. CHI has announced a research collaboration with the Woolcock Institute of Medical Research in Sydney, Australia to evaluate its Quattrii™ dry powder inhaler for pulmonary delivery of spray-dried nisin, an antimicrobial peptide. The laboratory programme to test aerosol delivery will investigate how nisin formulations perform in the Quattrii DPI engine and whether a combination therapy of nisin and the antibiotic colistin warrants further evaluation. The collaboration addresses a practical barrier in developing new inhaled medicines: translating a promising powder into a reliably delivered aerosol at a useful dose. For antimicrobials, like all formulations, understanding how powder loading, dispersion and device retention affect delivery and potential for further biological evaluation and development is an important step towards assessing their potential for further development. The Woolcock brings expertise in respiratory formulation science, device characterisation, and drug delivery. Its researchers will complete aerosol testing with Quattrii across powder loads of 18 to 45 mg to help establish how formulation and device performance interact at different fill masses. The programme will also include preliminary testing against biofilms known to be difficult to treat. The results will guide whether development of a nisin–colistin co-formulation should be progressed. Professor Daniela Traini, the Woolcock's Respiratory Technology Research Leader, said: “Developing an inhaled antimicrobial is not just about producing a powder. We need to understand how much drug can actually reach the lungs and whether it retains its biological activity. “Working with CHI gives us the opportunity to evaluate Quattrii for delivering high doses of spray-dried nisin and to explore whether combining nisin with colistin could improve activity against difficult-to-treat bacterial biofilms.” Quattrii’s high powder capacity and overall flexibility make it suitable for a wide range of fill masses. Its individual heat-sealed aluminium foil blisters protect the formulation from moisture up to the point of use, while its unique, patented powder deagglomeration engine enables industry leading aerosol delivery. Devices are available now in moulded medical-grade plastic for laboratory evaluation and clinical trials. Jamie Greenwood, Principal Scientist at Cambridge Healthcare Innovations, said: “Tomorrow’s inhaled medicines need more than what yesterday’s inhalers can offer. They need devices that provide an effective way to protect and present the dose while still achieving class leading aerosol delivery performance. “Devices which have the ability to deliver across a range of powder loads, including high doses are valuable for next generation therapies, including biologic drugs. This collaboration will examine that relationship directly with our Quattrii carrier free dry powder inhaler. “We are delighted to support the Woolcock’s research into antimicrobial peptides. This is aligned with our aim to give formulation developers the right delivery device technology to support their development journey.” The programme is a non-clinical research evaluation and does not include human studies. Its findings will inform subsequent formulation and device development decisions. About the Woolcock Institute of Medical Research The Woolcock Institute of Medical Research is an Australian research institute focused on respiratory and sleep health. Its Respiratory Technology group brings together expertise in drug formulation, device development, characterisation and delivery.", "url" : "https://chi.uk/chi-blog/the-woolcock-to-advance-inhaled-peptide-research-with-quattrii-dpi", "wordCount" : "596" } ``` ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Jamie Greenwood", "url" : "https://chi.uk/chi-blog/author/jamie-greenwood" }, "dateModified" : "2026-11-13T10:22:05.196Z", "datePublished" : "2026-11-13T10:22:05.000Z", "headline" : "The Woolcock to advance inhaled peptide research with Quattrii DPI", "image" : [ "https://chi.uk/hubfs/Quattrii-carrier-free.jpg" ], "mainEntityOfPage" : { "@id" : "https://chi.uk/chi-blog/the-woolcock-to-advance-inhaled-peptide-research-with-quattrii-dpi", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://chi.uk/hubfs/CHI.svg" }, "name" : "Cambridge Healthcare Innovations Ltd." } } ```